Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) EBIT Margin (2024 - 2025)

Historic EBIT Margin for Prime Medicine (PRME) over the last 2 years, with Q3 2025 value amounting to 4405.96%.

  • Prime Medicine's EBIT Margin rose 215423700.0% to 4405.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 3412.48%, marking a year-over-year increase of 248735200.0%. This contributed to the annual value of 6787.36% for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Prime Medicine's EBIT Margin stood at 4405.96%, which was up 215423700.0% from 4787.17% recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's EBIT Margin ranged from a high of 2025.74% in Q4 2024 and a low of 25948.33% during Q3 2024